Open Access

Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits

  • Yanli Wang1, 2,
  • Liang Bai1, 3Email author,
  • Yan Lin1, 3,
  • Yulong Chen4,
  • Hua Guan1, 3,
  • Ninghong Zhu1, 3,
  • Yafeng Li1, 3,
  • Shoucui Gao1, 3,
  • Lijing Sun1, 3,
  • Sihai Zhao1, 3,
  • Jianglin Fan5 and
  • Enqi Liu1, 3, 4
Lipids in Health and Disease201514:82

https://doi.org/10.1186/s12944-015-0083-5

Received: 18 March 2015

Accepted: 21 July 2015

Published: 29 July 2015

Abstract

Background

Atherosclerotic cardiovascular disease is one of the major diseases that seriously impacts human health. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events.

Aim

The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits.

Methods and Results

Thirty Japanese white rabbits were fed with a high cholesterol diet for 12 weeks, which was supplemented with either 0.005 % atorvastatin alone or 0.005 % atorvastatin plus 0.3 % probucol and 0.3 % cilostazol. Except for high-density lipoprotein cholesterol, no difference was found in plasma lipids among vehicle, statin, and the combined treatment group. However, atherosclerotic lesions were significantly reduced by statin treatment compared with vehicle. Moreover, we found that the anti-atherogenic effect of statin was further enhanced by the combined treatment, which was due to increased anti-inflammatory and anti-oxidant properties.

Conclusions

These data demonstrated that combined drug treatment exhibits potent athero-protective effects via pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect.

Keywords

AtorvastatinProbucolCilostazolAtherosclerosisRabbits

Introduction

Atherosclerotic cardiovascular disease (ASCVD) is the foremost cause of disability and mortality in both developed and developing countries [13]. Atherosclerosis is a multifactorial disease and progresses slowly throughout the human life; therefore treatment of atherosclerosis requires many therapeutic strategies. Statins, hydroxylmethyl glutaryl coenzyme A reductase inhibitors, are widely used for treating hyperlipidemia [47]. Although statins are the first choice for treatment of atherosclerosis [811], there are still many patients who are not responsive to statins. Actually, statins intolerance is frequently encountered in clinical practice [12, 13]. Therefore, it may be practical to consider the combined use of statins with other drugs for those unresponsive patients. Previous studies have shown that atorvastatin combined with probucol exhibited a stronger anti-atherogenic effect than single drug treatment [14]. Probucol, a diphenolic compound with anti-inflammatory and anti-oxidant properties, can reduce atherosclerosis and restenosis in coronary arteries [15, 16]. Cilostazol, an inhibitor of type 3 phosphodiesterase, is widely used for treating thrombotic vascular disease and exerts antiplatelet activity via suppression of cyclic adenosine monophosphate degradation [17, 18]. Our previous studies found that the combined use of probucol with cilostazol has a greater anti-atherogenic effect than single probucol treatment [19]. Rabbits fed with a cholesterol diet are readily to develop atherosclerotic lesions, which mimics the lesions observed in ASCVD patients [20]. However, whether combination of statins with probucol and cilostazol has an add-on effect on atherosclerosis in moderately hypercholesterolemic rabbits is still unknown.

In the current study, a rabbit model with moderately hypercholesterolemia was established by feeding a cholesterol diet. The effect of statins combined with probucol and cilostazol on atherosclerosis was investigated. We found that combined drug treatment significantly attenuated atherosclerosis through inhibiting anti-inflammatory and antioxidant properties independent of the lipid-lowering function.

Materials and methods

Animals and diets

Thirty Japanese white rabbits (male, 4-mon) were supplied by Vital River Laboratories, Beijing, China. The rabbits were randomly divided into three groups: vehicle group (n = 10); atorvastatin group (0.005 % atorvastatin, n = 10); and APC group (0.005 % atorvastatin + 0.3 % probucol + 0.3 % cilostazol, n = 10). All rabbits were fed a cholesterol diet containing 0.3 % cholesterol and 3 % soybean oil for 12 weeks.

The probucol and cilostazol were provided by Otsuka Pharmaceutical Co., Ltd. Tokushima, Japan. Atorvastatin calcium was purchased from Sequoia Research Products Ltd, Pangbourne, UK. The drugs were mixed with cholesterol diets and prepared by Ke’ao Xieli Diet Co., Ltd., Beijing, China. The drug concentrations in diet were measured using gas chromatography or high-performance liquid chromatographic methods as previously described [21, 22]. All rabbits were given a restricted diet (100 g/rabbit per day) and free access to water. The animal experiments were approved by the Laboratory Animal Administration Committee of Xi’an Jiaotong University and carried out according to the Guidelines for Animal Experimentation of Xi’an Jiaotong University and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication NO. 85–23, revised 2011).

Determination of plasma lipid levels and other biochemical parameters

Blood samples were collected from the ear artery using an EDTA anticoagulant tube after 16 h fasting. Plasma was obtained after centrifuging at 3000 rpm for 20 min. The plasma triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were determined by commercial assay kits (Biosino Bio-technology and Science Inc., Beijing, China). Plasma TC and TG levels were measured biweekly, while plasma HDL-C and LDL-C levels were measured every 4 weeks. In order to compare whole plasma lipid levels in 12 weeks among three groups, the incremental area under the curve (AUC) was calculated according to the trapezium rule [23].

The C-reactive protein (CRP) levels were quantified using an ELISA kit (Immunology Consultants Laboratory, Inc., Newberg, OR, USA). The plasma levels of superoxide dismutase (SOD) and malondialdehyde (MDA) were measured by xanthine oxidase assay and thiobarbituric acid assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), respectively, and oxidized LDL (ox-LDL) was measured by an ELISA kit (R&D Systems, Minneapolis, MN,USA).

Quantification of gross atherosclerotic lesions

At the end of the experiment, all rabbits were euthanized by intravenous injection of an overdose of sodium pentobarbital. Rabbit aortas were subsequently collected for analysis of the aortic lesions. Aortic en face atherosclerosis was evaluated after the aortic trees were stained with Sudan IV as previously described [24]. Sudanophilic area was quantified using image analysis software (WinROOF Ver.6.5, Mitani Co., Ltd., Fukui, Japan) and expressed as a percentage of the aorta.

Histology and immunohistochemistry

For the microscopic quantification of lesions, the aortic arch of each rabbit was cut into 8 to 10 sections (4 μm) as previously described [25]. To evaluate the microscopic lesion area of each aorta, all sections were stained with hematoxylin and eosin (HE), and measured by the image analysis system described above. For microscopic evaluation of cellular components in the lesions, serial paraffin sections of the aorta were immunohistochemically stained with the following antibodies (Abs) against macrophage (MФ) (RAM11, Dako, Carpinteria, CA, USA) and smooth muscle cells (SMC) (α-smooth muscle actin, Thermo Fisher Scientific Pierce, Rockford, IL, USA). Secondary Abs included anti-murine IgG (Beijing Zhongshan Biotechnology, Beijing, China) for MФ and SMC staining [25].

Lesion type and quantitation

We analyzed whether the combined drug treatment had any effect on the progression of atherosclerosis according to American Heart Association guidelines in which atherosclerotic lesions are divided into I-VI morphologically characteristic types [26, 27]. To quantify lesion types, the total length of each lesion in the aortic arch was calculated in three groups using a method as reported in our previous study [28].

Statistical analysis

The statistical analyses were carried out by one-way ANOVA followed by LSD test using the SPSS 13.0 software. In all cases, data were expressed as the mean ± SEM. P values less than 0.05 were considered statistically significant.

Results

Plasma lipid levels

As shown in Fig. 1, the plasma levels of TC, LDL-C and TG were not significantly different among three groups, while the HDL-C level was significantly lower in APC group than vehicle and statin groups, respectively. Overall, in this study, statin and APC treatment did not affect plasma TC and TG levels.
Fig. 1

Plasma lipid levels. Plasma cholesterol total cholesterol (TC) (a), low-density lipoprotein cholesterol (LDL-C) (b), triglyceride (TG) (c), and high-density lipoprotein cholesterol (HDL-C) levels (d) were measured every 2 or 4 weeks. Data are expressed as the mean ± SEM, n = 10 for each group. **P < 0.01 vs. vehicle or statin treatment group

The drug concentrations in each diet were confirmed by gas chromatography or high-performance liquid chromatographic as shown in Table 1. There was no difference in food intake or body weight among all groups (data not shown).
Table 1

Drug concentrations in diet from each group

Group

Atorvastatin

Probucol

Cilostazol

Vehicle

-

-

-

Atorvastatin

0.0037 %

-

-

APC

0.0039 %

0.2654 %

0.2491 %

Gross lesion of aortic atherosclerosis

In this experiment, even in the absence of a significant lipid-lowering effect, both statin and APC treatment led to a significant decrease in atherosclerotic gross lesions. Total atherosclerotic gross lesions were notably reduced by 85 % in APC treatment (P < 0.01) and 74 % in statin (P < 0.05) compared with vehicle (Fig. 2a and b). A similar reduction was found in all parts of the aortic tree, including the aortic arch, thoracic and abdominal aortas in APC compared to vehicle and statin groups (Fig. 2a and b). Apparently, the anti-atherogenic effect of combined triple drug therapy was efficacious than statin alone. Furthermore, this anti-atherogenic effect was not dependent of the lipid-lowering function of statins.
Fig. 2

Aortic atherosclerotic lesions. Aortic trees were stained with Sudan IV (a) and the lesion area was calculated in different parts of aorta (b). Data are expressed as the mean ± SEM, n = 10 for each group. *P < 0.05, **P < 0.01 vs. vehicle or statin treatment group

Histological examination

To quantify the size and components of atherosclerotic lesions, we measured the aortic arch sections using pathological analysis. Histological and immunohistochemical studies revealed that the intimal lesions and the positive area of MФ and SMC in statin group were reduced compared with the vehicle (Fig. 3). APC treatment significantly decreased the intimal lesions and the positive area of MФ and SMC compared with the vehicle (P < 0.05 or P < 0.01). Importantly, we found that the intimal lesions and the positive area of MФ and SMC in the APC group were further reduced compared with statin group (P < 0.05) (Fig. 3). These results suggest that APC treatment is more efficacious in inhibiting the intimal lesions and MФ and SMCs than stain treatment alone.
Fig. 3

Histological analysis of aortic atherosclerosis. Representative micrographs of the intimal lesions and cellular components (a) and morphometric analysis of intimal lesions, lesion positive area of macrophage (MФ) and smooth muscle cells (SMCs) in these lesions (b). Data are expressed as the mean ± SEM, n = 10 for each group. *P < 0.05, **P < 0.01 vs. vehicle or statin treatment group

Lesion type analysis

We further quantified the lesion types of the aortic arch in each group. We found that atherosclerotic lesions in cholesterol-fed rabbits were composed of type I, II and III lesions (Fig. 4). Although all types of lesions were reduced in both statin and APC groups, statistical significance was only found in APC group compared with the vehicle group (Fig. 4). Type III represents the stage that links type II to advanced lesions [26, 27].
Fig. 4

Lesions type analysis. Lesion types of the aortic arch were analyzed by microscope in each group (a). Lesion types I-III was quantified, respectively (b). Data are expressed as the mean ± SEM, n = 10 for each group. *P < 0.05 vs. vehicle

Inflammatory and oxidation markers

To explore the possible mechanisms underlying APC anti-atherogenic effects, we measured plasma levels of SOD, MDA, ox-LDL and CRP at 12 weeks. As shown in Fig. 5, plasma SOD levels were significantly increased in the APC group (P = 0.04), while plasma MDA (even though not statistically different), ox-LDL and CRP levels were reduced in both APC and statin groups compared to vehicle (Fig. 5a-d).
Fig. 5

Oxidative stress and inflammation markers. Plasma superoxide dismutase (SOD) (a), malonaldehyde (MDA) (b), oxidized low-density lipoprotein (ox-LDL) (c) and C-reactive protein (CRP) levels (d) were measured at 12 weeks. Data are expressed as the mean ± SEM, n = 8 or 10 for each group. *P < 0.05, **P < 0.01 vs. vehicle or statin treatment group

Discussion

Risk factors for atherosclerosis, such as dyslipidemia, inflammation, oxidative stress, abnormal levels of coagulant and central obesity often co-exist [29]. The present study provides evidence that the combined drug therapy consisting of probucol, cilostazol and atorvastatin markedly enhances the statin anti-atherogenic effect independent of a lipid-lowering manner in moderately hypercholesterolemic rabbit model.

In this experiment, rabbit model had moderate hypercholesterolemia (plasma TC = 350–500 mg/dl) compared to our previous studies (rabbit plasma TC = 800–1200 mg/dl) [19, 24, 25, 30, 31]. We used this model to investigate the effect of combined drug treatment in the early stages of atherosclerosis and found that, except for HDL-C, plasma lipids were not affected after 12 weeks of drug treatment. This was possibly due to the “relatively low” hypercholesterolemia baseline in these rabbits. However, APC treated group had lower HDL-C levels, which was caused by the presence of probucol. In spite of this, HDL functions were not impaired but were actually more efficient for reverse cholesterol transport(RCT) [3235]. Previous studies have revealed that cholesterol ester transfer protein (CETP) plays a crucial role in mediating HDL functions and probucol may enhance reverse cholesterol transport by increasing CETP expression. HDLs mediated by enhanced CETP activity showed potentially anti-atherogenic functions [34]. In our previous study, we measured hepatic LDL receptor, SR-B1, ABCA1, CETP mRNA and protein expression levels and found that all drug treatment groups significantly increased hepatic LDL receptor mRNA expression by which hepatic uptake of LDLs would be enhanced (data not shown). Interestingly, we found combination treatment synergistically increased CETP mRNA and protein expression level in liver (data not shown). CETP as a plasma glycoprotein transfers CE from HDL to apoB-containing lipoproteins in exchange for triglycerides. Thus, directly through hepatic SR-B1 receptor uptake or indirectly through transfer of HDL-CE to ApoB-containing lipoproteins with subsequent receptor-mediated hepatic uptake, CETP could contribute significantly to the RCT pathway [36, 37].

Statins dramatically reduced cardiovascular events in patients with normal lipid levels or without established ASCVD, independently from lipid-lowering properties [38]. Moreover, plasma cholesterol lowering does not necessarily lead to protection against cardiovascular disease. In the present study, the attenuation of atherosclerotic lesions in APC treated group was independent of lipid-lowering function. These findings may be consistent with the “Mevalonate hypothesis” proposed recently [39] and further studies are needed for verifying. The anti-atherosclerosis in APC treatment may be due to their multiple pharmacological properties, such as enhanced anti-inflammatory and anti-oxidant effects in APC treatment group. Elevations in inflammatory markers, such as CRP, prospectively define the risk of atherosclerotic complications [31, 40, 41]. In the present study, plasma levels of CRP and ox-LDL were notably reduced in APC treated group compared to vehicle. Furthermore, SOD levels were significantly increased, while MDA levels simultaneously decreased in the APC treated group compared to vehicle. Statins as well as cilostazol, also known as platelet-activating factor inhibitors, play an important role in the crosstalk of dyslipidemia, inflammation and atherogenesis [4246]. In the moderate hypercholesterolemia rabbit model, we found that combination treatment (statins, cilostazol and probucol) decreases atherogenesis via pleiotropic effects, such as anti-inflammation, anti-oxidation and inhibition of platelet-activating factor.

Although it remains to be verified clinically whether combined APC treatment exhibits a “potent anti-atherogenic function”, it seems that APC more strongly attenuates the progression of atherosclerosis than statin alone in cholesterol-fed rabbits. These insights may provide us with a new concept with which to effectively delay the occurrence of cardiovascular events by APC combined drug treatment in the early stages for those patients with or without established ASCVD.

Declarations

Acknowledgements

This work was partly supported by the National Natural Science Foundation of China (81200207, 81270348), by a Public Service Platform Grant of Shaanxi Province (2014FWPT-07), and by Otsuka Pharmaceutical Co., Ltd.

Authors’ Affiliations

(1)
Research Institute of Atherosclerotic Disease, Xi’an Jiaotong University Cardiovascular Research Center
(2)
Department of Pathology, Xi’an Medical University
(3)
Laboratory Animal Center, Xi’an Jiaotong University School of Medicine
(4)
Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University
(5)
Department of Molecular Pathology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi

References

  1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Rev Esp Cardiol. 2011;64:1168.e1–1168.e60.View ArticleGoogle Scholar
  2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.PubMedView ArticleGoogle Scholar
  3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.PubMed CentralPubMedView ArticleGoogle Scholar
  4. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedView ArticleGoogle Scholar
  5. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedView ArticleGoogle Scholar
  6. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160:785–94.PubMedView ArticleGoogle Scholar
  7. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007;194:1–45.PubMedView ArticleGoogle Scholar
  8. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106:2041–2.PubMedView ArticleGoogle Scholar
  9. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426–31.PubMedView ArticleGoogle Scholar
  10. Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109:II18–26.PubMedView ArticleGoogle Scholar
  11. Wang ZH, Liu XL, Zhong M, Zhang LP, Shang YY, Hu XY, et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010;50:311–9.PubMedView ArticleGoogle Scholar
  12. Arca M, Pigna G, Favoccia C. Management of statin-intolerant patient. Panminerva Med. 2012;54:105–18.PubMedGoogle Scholar
  13. Cooney MT, Dudina A, D’Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? Circulation. 2010;122:300–10.PubMedView ArticleGoogle Scholar
  14. Keyamura Y, Nagano C, Kohashi M, Niimi M, Nozako M, Koyama T, et al. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. PLoS One. 2014;9:e96929.PubMed CentralPubMedView ArticleGoogle Scholar
  15. Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989;98:612–8.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207:16–23.PubMedView ArticleGoogle Scholar
  17. Weintraub WS. The vascular effects of cilostazol. Can J Cardiol. 2006;22:56B–60B.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366–98.PubMedView ArticleGoogle Scholar
  19. Chen YL, Zhao SH, Huang BQ, Wang YL, Li YF, Waqar AB, et al. Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits. Thromb Res. 2013;132:565–71.PubMedView ArticleGoogle Scholar
  20. Fan JL, Watanabe T. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther. 2003;99:261–82.PubMedView ArticleGoogle Scholar
  21. Satonin DK, Coutant JE. Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma. J Chromatogr. 1986;380:401–6.PubMedView ArticleGoogle Scholar
  22. Fu CJ, Tata PN, Okada K, Akiyama H, Bramer SL. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B. 1999;728:251–62.View ArticleGoogle Scholar
  23. Liu EQ, Kitajima S, Higaki Y, Morimoto M, Sun HJ, Watanabe T, et al. High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. Metabolism. 2005;54:132–8.PubMedView ArticleGoogle Scholar
  24. Zhang CF, Zheng HD, Yu Q, Yang PG, Li YF, Cheng F, et al. A practical method for quantifying atherosclerotic lesions in rabbits. J Comp Pathol. 2010;142:122–8.PubMedView ArticleGoogle Scholar
  25. Wang YL, Cheng F, Chen YL, Li YF, Zhao SH, Yu Q, et al. High-dose rosiglitazone is pro-atherogenic in cholesterol-fed rabbits. Atherosclerosis. 2012;222:292–4.PubMedView ArticleGoogle Scholar
  26. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull Jr W, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462–78.PubMedView ArticleGoogle Scholar
  27. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull Jr W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355–74.PubMedView ArticleGoogle Scholar
  28. Li S, Liang J, Niimi M, Waqar AB, Kang D, Koike T, et al. Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. J Atheroscler Thromb. 2014;21:648–58.PubMedView ArticleGoogle Scholar
  29. Smith Jr SC, Grundy SM. 2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. J Am Coll Cardiol. 2014;64:601–12.PubMedView ArticleGoogle Scholar
  30. Wang YL, Bai L, Lin Y, Guan H, Zhu NH, Chen YL, et al. Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects. Histol Histopathol. 2014;29:1593–600.PubMedGoogle Scholar
  31. Yu Q, Li YF, Wang YL, Zhao SH, Yang PG, Chen YL, et al. C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol. 2012;27:529–35.PubMedGoogle Scholar
  32. Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation. 2011;124:1382–90.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol. 2005;25:2422–7.PubMedView ArticleGoogle Scholar
  34. Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997;27:285–92.PubMedView ArticleGoogle Scholar
  35. Lau AK, Leichtweis SB, Hume P, Mashima R, Hou JY, Chaufour X, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003;107:2031–6.PubMedView ArticleGoogle Scholar
  36. Oliveira HC, de Faria EC. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life. 2011;63:248–57.PubMedView ArticleGoogle Scholar
  37. Sirtori CR. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert Opin Investig Drugs. 2011;20:1543–54.PubMedView ArticleGoogle Scholar
  38. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.PubMed CentralPubMedView ArticleGoogle Scholar
  39. Keizer HG. The “Mevalonate hypothesis”: a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis. 2012;11:149.PubMed CentralPubMedView ArticleGoogle Scholar
  40. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.PubMedView ArticleGoogle Scholar
  41. Sun HJ, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167:1139–48.PubMed CentralPubMedView ArticleGoogle Scholar
  42. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011;62:209–18.PubMedView ArticleGoogle Scholar
  43. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor- a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105:705–16.View ArticleGoogle Scholar
  44. Liapikos TA, Antonopoulou S, Karabina SP, Tsoukatos DC, Demopoulos CA, Tselepis AD. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim Biophys Acta. 1994;1212(3):353–60.PubMedView ArticleGoogle Scholar
  45. Tsantila N, Karantonis HC, Perrea DN, Theocharis SE, Iliopoulos DG, Iatrou C, et al. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. Nutr Metab Cardiovasc Dis. 2010;20:740–7.PubMedView ArticleGoogle Scholar
  46. Detopoulou P, Demopoulos CA, Karantonis HC, Antonopoulou S. Mediterranean diet and its protective mechanisms against cardiovascular disease: An insight into Platelet Activating Factor (PAF) and diet interplay. Annals of Nutritional Disorders and Therapy. 2015;2:1–10.Google Scholar

Copyright

© Wang et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement